Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 5 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.

HPV DNA vaccine shows therapeutic potential in patients with cervical intraepithelial neoplasia 3

25 Apr 2020

The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.

Seventy-two CIN3 patients positive for HPV type 16/18 were randomized to receive to receive GX-188E at either 1 or 4 mg. Treatment was administered intramuscularly at weeks 0, 4 and 12. Histopathologic regression to ≤CIN1 was assessed at week 20, as well as at week 36 in an extension study. Researchers performed HPV-sequencing analysis and an ex vivo IFNγ ELISpot assay using the collected cervical biopsy and blood samples from patients.

Of the patients, 64 patients were included in per-protocol analysis and 52 in extension analysis. Histopathologic regression with GX-188E overall occurred in 33 patients (52 percent) at week 20 and in 35 patients (67 percent) at week 36.

Furthermore, HPV clearance was achieved by 73 percent and 77 percent of patients with histologic regression at weeks 20 and 36, respectively. HPV clearance was significantly associated with histopathologic regression at both time points.

Patients with HPV clearance at week 36 exhibited significantly greater changes in their IFNγ ELISpot responses relative to those without HPV clearance. The HPV type 16 E6/E7 variants D25E, V83L and N29S had an inverse association with histopathologic regression at week 36.

More studies are needed to evaluate the therapeutic effect of the GX-188E vs placebo against HPV type 16/18–associated CIN3, as well as to examine the potential of tailoring HPV therapeutic vaccine according to individual HPV variants, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Jul 2020
Adjunctive perampanel appears to be safe and effective for long-term treatment of patients with tonic‐clonic seizures, according to a posthoc analysis.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Elaine Soliven, 5 days ago
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Jairia Dela Cruz, 18 Feb 2020
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.